

Mehmet H Kocoglu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7127738/publications.pdf>

Version: 2024-02-01

16
papers

344
citations

1307594

7
h-index

1199594

12
g-index

17
all docs

17
docs citations

17
times ranked

746
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review. <i>British Journal of Ophthalmology</i> , 2023, 107, 901-905. | 3.9 | 3 |
| 2 | Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 686-689. | 5.2 | 19 |
| 3 | Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1339-1347. | 1.3 | 6 |
| 4 | Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e716-e729. | 0.4 | 2 |
| 5 | Revisiting the Case of Sarah Newbury's Death from Mollities Ossium. <i>Cancer Investigation</i> , 2022, , 1-10. | 1.3 | 0 |
| 6 | Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy. <i>Blood</i> , 2022, 140, 152-156. | 1.4 | 17 |
| 7 | Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. <i>Neuro-Oncology</i> , 2021, 23, 112-121. | 1.2 | 53 |
| 8 | An Unusual Cause of a Pathological Vertebral Fracture: Solitary Plasmacytoma. <i>American Journal of the Medical Sciences</i> , 2020, 360, 206-207. | 1.1 | 0 |
| 9 | Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond. <i>Expert Review of Hematology</i> , 2020, 13, 669-686. | 2.2 | 8 |
| 10 | Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3577-3580. | 1.3 | 1 |
| 11 | Refractory postallogeic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. <i>American Journal of Hematology</i> , 2019, 94, E216-E219. | 4.1 | 23 |
| 12 | Therapeutic strategies for durable response in plasma cell granulomas in the central nervous system. <i>Annals of Hematology</i> , 2019, 98, 1027-1029. | 1.8 | 5 |
| 13 | Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. <i>Blood</i> , 2017, 130, 1189-1197. | 1.4 | 169 |
| 14 | The Role of Immunotherapy in Multiple Myeloma. <i>Pharmaceuticals</i> , 2016, 9, 3. | 3.8 | 23 |
| 15 | Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016, 128, 490-490. | 1.4 | 15 |
| 16 | Racial Differences in Molecular Cytogenetic Abnormalities in Black and White Patients with Multiple Myeloma (MM): A Single-Center Experience. <i>Blood</i> , 2015, 126, 1767-1767. | 1.4 | 0 |